Medetomidine: The dangerous veterinary sedative turning up in Scotland’s street drugs

The Conversation UK reports on medetomidine, a veterinary sedative that has begun to appear in Scotland’s illicit drug supply, raising urgent safety concerns. It explains what medetomidine is, how it differs from opioids, its prevalence in street drugs, the lack of a proven human antidote, and recent policy recommendations. This briefing from The Conversation provides context for public health and first responders grappling with a compound that can cause severe cardiovascular reactions and requires careful handling in treatment decisions.

• Medetomidine explained: a powerful veterinary sedative now found in illicit drugs
• Prevalence: found in about 20% of Scottish heroin samples; widespread in US fentanyl samples
• Overdose risk: no proven reversal for humans; veterinary antidote exists (atipamezole) but can trigger dangerous reactions in people
• Policy context: UK Advisory Council on the Misuse of Drugs recommendations and pending government response

Overview

The Conversation UK examines medetomidine, a sedative developed for veterinary use more than five decades ago, and its emergence in Scotland’s street-drug supply. The article notes that medetomidine has been detected in about 20% of heroin samples tested between April and July, signaling a growing public health concern. The drug is often mixed with other substances rather than sold alone, complicating overdose responses and clinical management. A key theme is the lack of a proven antidote for medetomidine overdoses in humans, contrasted with veterinary reversal agents, and the need for better detection and response strategies in emergency settings.

What is medetomidine and why is it dangerous?

Medetomidine is closely related to xylazine, another veterinary sedative that has appeared in illicit drugs in North America and the UK. Both drugs act on alpha-adrenergic receptors and can narrow blood vessels. Medetomidine is far more potent than xylazine, with very small doses capable of producing strong physiological effects. Unlike opioids, medetomidine reduces activity in a brain region involved in wakefulness (the locus coeruleus) and does not directly depress respiration in the same way opioids do. The combination of medetomidine with opioids can lead to multi-system adverse effects, including dangerous changes in blood pressure and heart rate, sometimes followed by a rebound of instability.

Prevalence in illicit drugs

Beyond Scotland, the article cites a striking prevalence in North America. In Philadelphia, an estimated 83% of fentanyl samples tested between 2024 and 2025 contained medetomidine. In the UK, the drug has shown up “regularly” in street benzodiazepines and has been found in a fifth of Scottish heroin samples tested in a specified window. These findings indicate a broader issue of medetomidine being used to adulterate or enhance other street drugs, raising the risk profile for users and complicating treatment protocols for overdose or adverse reactions.

Overdose risks and treatment options

Naloxone reverses opioid overdoses but there is no approved reversal agent for medetomidine overdose in humans. In animals, a drug called atipamezole reverses medetomidine’s effects, but reversing it too quickly in people can trigger withdrawal-like symptoms, including vomiting, tachycardia, and a spike in blood pressure. The distinct mechanism of medetomidine, which reduces wakefulness via the locus coeruleus, differentiates it from opioids that suppress breathing, and this combination can yield dangerous, multi-system effects when used with opioids. The absence of a safe, proven human antidote underscores the need for cautious clinical management, increased awareness among first responders, and the development of appropriate reversal strategies that minimize rebound effects.

Origins, supply chains, and what can be done

Supply origins are described as murky. In the US, medetomidine may be diverted illegally from veterinary supplies or produced illicitly. The article notes that China is a known source country for xylazine; however, the precise origins and routes for medetomidine are less clear. In the near term, public health measures such as safe drug consumption spaces, testing and monitoring, and a push for a safe reversal drug are highlighted as priorities. Testing capabilities exist for xylazine but not yet for medetomidine, and lab testing remains the most reliable method to identify medetomidine in a sample and tailor response. There is a call for replacing or enhancing existing public information resources and training for emergency responders to recognize medetomidine’s effects and respond effectively.

Policy responses and recommendations

In October 2025, the UK Advisory Council on the Misuse of Drugs issued three recommendations: classify medetomidine as a class C drug, train emergency responders about its effects, and update public information platforms such as Talk to Frank; and ensure border-control labs routinely test seized drugs for medetomidine. The UK government’s response was pending at the time of the report. The article stresses that addressing medetomidine requires a combination of public health intervention, regulatory action, laboratory capacity, and ongoing surveillance to mitigate risk to drug users and first responders.

Implications for public health and future directions

The analysis underscores the evolving landscape of illicit drug composition and the importance of cross-sector collaboration among health services, law enforcement, policymakers, and communities. The emergence of potent veterinary sedatives in street drugs highlights vulnerabilities in drug supply chains and the urgent need for better detection, clinical guidance, and treatment options. The Conversation frames medetomidine as a growing threat that requires evidence-based policy responses and practical on-the-ground measures to protect public health and safety.